December 10th & 11th, 2026
15th edition
MARSEILLE, FR

Thinking of the exit scenario to shape a biotech start-up at its first steps: Which model for which term of exit?

Thinking of the exit scenario to shape a biotech start-up at its first steps: Which model for which term of exit?

When creating a biotech start-up, different routes can be taken: the virtual biotech model, the technology platform model, the one single asset company… How do those initial choices influence the exit scenario of the company?

Mark Krul

Partner
Aglaia BioMedical Ventures

Lucie Ellis

Managing Editor
In Vivo Pharma Intelligence | Informa

Rodolphe Besserve

Head SuFT Advisory, Start-ups & French Techs
Société Générale Corporate Investments and Banking

George Hoffmann

Co-founder and CEO
Network Immunology

Peter Leonardi

CEO
OmniCyte
Scroll to Top

Before you leave…

Download the official BioFIT 2026 brochure

Discover the conference programme, partnership opportunities, attendee profiles, registration options and everything you need to make the most of BioFIT 2026.